News

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 ...
The Manila Times27m
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...
The Manila Times28m
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with ...
Aptevo Therapeutics: Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among ...
BERNAMA1h
Death Of Family Of Four: Trailer Driver Gets 8 Years’ Jail, RM80,000 Fine
TAIPING, June 18 (Bernama) -- A trailer driver was sentenced to eight years in prison and fined RM80,000 by the High Court ...